Gary Schwartz: Monica Bertagnolli is poised to be a visionary NIH director

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

As Case Comprehensive Cancer Center’s new director, and on behalf of our membership, I applaud the Biden administration for tapping Monica Bertagnolli, MD, FASCO, as the second female director of the National Institutes of Health (NIH) and congratulate Dr. Bertagnolli on her candidacy. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Gary Schwartz, MD
Director, Case Comprehensive Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

The day before health economist Jay Bhattacharya stepped into his new role as NIH director, he sent a document to his employees outlining his top five priorities for the department, which included “reproducibility” and “transparency,” two themes he discussed at his confirmation hearings (The Cancer Letter, March 7, 2025).
A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.
Gary Schwartz, MD
Director, Case Comprehensive Cancer Center

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login